Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line
- PMID: 1873810
Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line
Abstract
The effects of four anti-GM2 monoclonal antibodies (DMAb-1, DMAb-2, DMAb-3, and DMAb-5) were studied on spheroid cultures from a human glioma cell line (D-54 MG) that is known to express high levels of GM2. The spheroids developed central necrosis 48 h after antibody exposures at concentrations greater than 6 micrograms/ml. No necrosis was found with antibodies that had been absorbed with GM2 prior to exposure or with unrelated cytotoxic antibodies. Immunohistochemistry showed that the necrosis started shortly after the antibodies were evenly distributed throughout the spheroids. Light and transmission electron microscopy revealed that a small portion of the cells, mainly in the periphery of the spheroids, was unaffected by antibody exposure. New monolayer cultures established from antibody-treated cells expressed a 50% lower GM2 content as shown by flow cytometry and determination of ganglioside content throughout at least 12 passages. Thus, the GM2-rich D-54 MG cell line has subpopulations of cells with lower GM2 content. Spheroids obtained from this subpopulation developed only minor necrosis after antibody treatment. These results show that GM2 antibodies cause severe necrosis of GM2-containing glioma cells in vitro, but the effect depends on the concentration of antigen, and a threshold number of GM2 molecules is required.
Similar articles
-
Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.Cancer Res. 1989 Dec 1;49(23):6645-51. Cancer Res. 1989. PMID: 2479468
-
Chimeric anti-ganglioside GM2 antibody with antitumor activity.Cancer Res. 1994 Mar 15;54(6):1511-6. Cancer Res. 1994. PMID: 8137257
-
Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody.Cancer Res. 1999 Oct 15;59(20):5323-30. Cancer Res. 1999. PMID: 10537316
-
Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.Cancer Res. 2005 Jul 15;65(14):6425-34. doi: 10.1158/0008-5472.CAN-05-0300. Cancer Res. 2005. PMID: 16024647
-
Complement-mediated anti-HIV-1 effect induced by human IgM monoclonal antibody against ganglioside GM2.J Immunol. 1999 Jan 1;162(1):533-9. J Immunol. 1999. PMID: 9886430
Cited by
-
In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line.Glycoconj J. 1996 Jun;13(3):391-9. doi: 10.1007/BF00731472. Glycoconj J. 1996. PMID: 8781970
-
Effects of growth factors on a human glioma cell line during invasion into rat brain aggregates in culture.Acta Neuropathol. 1992;84(2):190-7. doi: 10.1007/BF00311394. Acta Neuropathol. 1992. PMID: 1523973
-
Glycan engagement dictates hydrocephalus induction by serotype 1 reovirus.mBio. 2015 Mar 3;6(2):e02356. doi: 10.1128/mBio.02356-14. mBio. 2015. PMID: 25736887 Free PMC article.
-
Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro.Glycoconj J. 2000 Oct;17(10):717-26. doi: 10.1023/a:1011026823362. Glycoconj J. 2000. PMID: 11425192